Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: treatment

First Posted Date: 2015-03-19

Last Posted Date: 2025-02-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 817

Registration Number: NCT02392455

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

Phase 1

Completed

Conditions: Schizophrenia
Alzheimer Disease

Interventions: Drug: Placebo matching BI 409306 25 mg
Drug: Placebo matching BI 409306 50 mg
Drug: BI 409306 25 mg
Drug: BI 409306 50 mg

First Posted Date: 2015-03-19

Last Posted Date: 2024-04-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 61

Registration Number: NCT02392468

Locations: 🇺🇸
Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States
🇺🇸
Community Clinical Research, Inc., Austin, Texas, United States
🇺🇸
University of California San Diego, La Jolla, California, United States

Asthma Biomarker Study

Completed

Conditions: Asthma

Interventions: Procedure: Biofluid sampling

First Posted Date: 2015-03-19

Last Posted Date: 2018-08-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 69

Registration Number: NCT02392481

Locations: 🇬🇧
352.2087.44001 Boehringer Ingelheim Investigational Site, Leicester, United Kingdom
🇬🇧
352.2087.44004 Boehringer Ingelheim Investigational Site, London, United Kingdom
🇬🇧
352.2087.44002 Boehringer Ingelheim Investigational Site, Manchester, United Kingdom

and more 1 locations

Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 425809

First Posted Date: 2015-03-10

Last Posted Date: 2015-08-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 49

Registration Number: NCT02383888

Locations: 🇰🇷
1346.4.82001 Boehringer Ingelheim Investigational Site, Busan, Korea, Republic of

Trial of Afatinib in Pediatric Tumours

Phase 1

Completed

Conditions: Neuroectodermal Tumors
Rhabdomyosarcoma

Interventions: Drug: afatinib

First Posted Date: 2015-02-26

Last Posted Date: 2021-03-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT02372006

Locations: 🇫🇷
INS Curie, Paris, France
🇦🇺
Sydney Childrens Hospital, Randwick, New South Wales, Australia
🇫🇷
HOP Pellegrin, Bordeaux, France

and more 25 locations

Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: JARDIANCE®

First Posted Date: 2015-02-20

Last Posted Date: 2024-03-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 419

Registration Number: NCT02367131

Locations: 🇯🇵
NISND Center, Multiple Locations, Japan

Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 425809

First Posted Date: 2015-02-13

Last Posted Date: 2015-07-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 25

Registration Number: NCT02362516

Locations: 🇧🇪
1346.3.32001 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

Phase 4

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Dabigatran Etexilate 150mg
Drug: Warfarin

First Posted Date: 2015-01-28

Last Posted Date: 2018-01-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 678

Registration Number: NCT02348723

Locations: 🇺🇸
Mercy Medical Group, a service of Dignity Health Medical Foundation, Sacramento, California, United States
🇺🇸
Southwest Florida Research, LLC, Naples, Florida, United States
🇺🇸
University of California, San Francisco, California, United States

and more 83 locations

Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: Omeprazole
Drug: Midazolam
Drug: Warfarin
Drug: Digoxin
Drug: BI 1181181

First Posted Date: 2015-01-26

Last Posted Date: 2015-03-10

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT02345304

Locations: 🇩🇪
1344.3.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Relative Bioavailability of a Single Oral Dose of BI 425809 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 425809
Drug: Itraconazole

First Posted Date: 2015-01-21

Last Posted Date: 2015-04-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02342717

Locations: 🇩🇪
1346.10.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy